Pitch Engine

Times Advertising


.

Why Headless CMS Is Critical for Cross-Border Brand Consistency: Building One Global Voice Across Many Markets

The larger a brand grows, the easier it becomes to jeopardize consistent communications. Brand experiences are impacted across different languages, cultures, legalities and marketing strat...

Using Structured Content to Build Multi-Step Marketing Funnels: A Scalable Framework for Guided Conversion

Multi-step marketing funnels aim to take users from awareness to conversion and through subsequent stages. Where basic funnels capture all momentum on one landing page, modern marketing ef...

From Pages to Components: How Headless CMS Changes Content Strategy

For years, content strategy was all about pages. Websites were created, written, designed, and optimized one by one, with content closely connected to placement and presentation. It made s...

Supporting Real-Time Interfaces with API-First Content Systems

Real-time interfaces have changed user expectations across many digital solutions. From live data dashboards to conversational interfaces and collaborative platforms, in-app alerts and con...

Biosafety Cabinet vs Ductless Fume Hood: Engineering Safety in Modern Laboratories

Why Containment Equipment Defines Research Integrity The modern laboratory is an environment of controlled risks. Whether handling infectious microorganisms or volatile organic solvents, ...

How Small Businesses Can Compete With Big Brands In Media Coverage?

Corporations with massive marketing expenditures are no longer the sole beneficiaries of media exposure in the contemporary digital era. Small businesses now have access to tools, platforms...

新加坡 - Media OutReach Newswire - 2024年3月18日 - 亚洲领先的医疗健康解决方案公司裕利医药宣布扩大与Karo Healthcare（"Karo"）的商业化合作伙伴关系。Karo成立于1987年，是一家领先的欧洲消费者医疗保健公司，总部位于瑞典斯德哥尔摩，产品远销90多个国家和地区。 根据新协议，裕利医药将成为Karo非处方药（OTC）品牌Lamisil®的独家商业化合作伙伴，该产品用于治疗香港、马来西亚、菲律宾、新加坡、韩国、台湾和越南的真菌感染。裕利医药的商业部门ZP Therapeutics拥有行业首屈一指的亚洲医疗健康专业人才以及丰富的零售药店与市场商业专业知识，将为这一合作伙伴关系提供指导。 自2019年以来，裕利医药就与Karo针对其在菲律宾、越南、新加坡和印度尼西亚的产品组合建立了强有力的商业化合作伙伴关系。 "我们很高兴能与Karo合作，扩大其产品的使用范围和可用性。裕利医药集团首席执行官John Graham表示："作为一家综合医疗保健解决方案公司，随着我们在韩国和台湾等关键市场的发展，这一合作伙伴关系也将在加强裕利医药的消费者健康投资组合方面发挥关键作用。"我相信，要扩大亚洲高需求的消费保健产品的市场覆盖面，裕利医药广泛的合作伙伴网络和经过验证的商业专业知识至关重要。" Hashtag: #ZuelligPharma #ZPTherapeutics #KaroHealthcare #Healthcare #Drugs #Medicines #ConsumerHealthcare

发布方对本公告的内容全权负责。

关于裕利医药（Zuellig Pharma）

裕利医药是亚洲最大的医疗健康服务供应商之一，以「让医疗服务更普及」为愿景。我们提供国际顶尖的分销、数字化和商业服务，以支持该地区日益增长的医疗需求。裕利医药自创立一百多年以来，已发展成市值数百亿美元的企业，覆盖16个市场，拥有12,000多名员工。我们的员工为超过20万家医疗机构提供服务，合作客户超过450家，其中不乏全球排名前20名的国际制药公司。 ZP Therapeutics，是裕利医药旗下的业务部门之一，是医疗健康行业值得信赖的商业化合作伙伴，在亚洲 13 个国家设有办事处，拥有超过 2,500 多名员工。 ZP Therapeutics 通过卓越的商业水准、高超的市场能力和严格的道德操守，成为改善患者体验和医疗健康成果的催化剂，是扩大患者供给渠道为医疗健康界提供创新的值得信赖的合作伙伴 欲了解更多资讯，请访问:

Source https://www.media-outreach.com/news/singapore/2024/03/18/283726/

hacklink hack forum hacklink film izle hacklink testjetbahistipobetslogan bahis sitesicasino not on gamstopiptv satın aliptv satın aliptv satın alcasibompadişahbetgalabet girişcasibommarsbahisjojobetpadişahbetikimislijojobetxslotenbetcasinoroyalmeritkingkingroyal